Handke J, Scholz AS, Dehne S, et al. - Researchers sought to validate the prognostic utility of presepsin for major adverse cardiovascular and cerebrovascular events (MACCE) after noncardiac surgery. Among a total of 222 enrolled CAD patients who were undergoing elective, inpatient noncardiac surgery, 23 (10%) patients were diagnosed with MACCE. Preoperative presepsin was elevated in MACCE patients. Raised 30-day MACCE rate was observed in correlation with presepsin exceeding the previously derived threshold of 184 pg ml⁻¹. Observations revealed independent predictive value of raised preoperative presepsin for 30-day MACCE in CAD patients undergoing major noncardiac surgery. Complementing cardiovascular risk prediction by inflammatory biomarkers, such as presepsin, may improve peri-operative care. However, there was only moderate prediction accuracy of presepsin, further validation studies are required.